These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33489011)

  • 1. Structure and compositional analysis of aluminum oxyhydroxide adsorbed pertussis vaccine.
    Duprez J; Kalbfleisch K; Deshmukh S; Payne J; Haer M; Williams W; Durowoju I; Kirkitadze M
    Comput Struct Biotechnol J; 2021; 19():439-447. PubMed ID: 33489011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum hydroxide adjuvant diverts the uptake and trafficking of genetically detoxified pertussis toxin to lysosomes in macrophages.
    Jaldin-Fincati J; Moussaoui S; Gimenez MC; Ho CY; Lancaster CE; Botelho R; Ausar F; Brookes R; Terebiznik M
    Mol Microbiol; 2022 May; 117(5):1173-1195. PubMed ID: 35344242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL
    Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identity, Structure and Compositional Analysis of Aluminum Phosphate Adsorbed Pediatric Quadrivalent and Pentavalent Vaccines.
    Kalbfleisch K; Deshmukh S; Mei C; Ore M; Williams W; Durowoju I; Duprez J; Morin S; Carpick B; Kirkitadze M
    Comput Struct Biotechnol J; 2019; 17():14-20. PubMed ID: 30581540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminum Phosphate Vaccine Adjuvant: Analysis of Composition and Size Using Off-Line and In-Line Tools.
    Mei C; Deshmukh S; Cronin J; Cong S; Chapman D; Lazaris N; Sampaleanu L; Schacht U; Drolet-Vives K; Ore M; Morin S; Carpick B; Balmer M; Kirkitadze M
    Comput Struct Biotechnol J; 2019; 17():1184-1194. PubMed ID: 31528298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAT solutions to monitor adsorption of Tetanus Toxoid with aluminum adjuvants.
    Haer M; Strahlendorf K; Payne J; Jung R; Xiao E; Mirabel C; Rahman N; Kowal P; Gemmiti G; Cronin JT; Gable T; Park-Lee K; Drolet-Vives K; Balmer M; Kirkitadze M
    J Pharm Biomed Anal; 2021 May; 198():114013. PubMed ID: 33713883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.
    Ausar SF; Zhu S; Duprez J; Cohen M; Bertrand T; Steier V; Wilson DJ; Li S; Sheung A; Brookes RH; Pedyczak A; Rak A; Andrew James D
    Commun Biol; 2020 Aug; 3(1):427. PubMed ID: 32759959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a droplet digital PCR for pertussis toxin locus copy number determination in a genetically-modified Bordetella pertussis strain.
    Esson R; Falque S; Abachin E; George S; Nougarede N
    Biologicals; 2023 May; 82():101683. PubMed ID: 37149976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
    Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
    Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
    Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
    Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.
    Acosta AM; DeBolt C; Tasslimi A; Lewis M; Stewart LK; Misegades LK; Messonnier NE; Clark TA; Martin SW; Patel M
    Pediatrics; 2015 Jun; 135(6):981-9. PubMed ID: 25941309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG 1018® adjuvant enhances Tdap immune responses against Bordetella pertussis in mice.
    DeJong MA; Wolf MA; Bitzer GJ; Hall JM; Sen-Kilic E; Blake JM; Petty JE; Wong TY; Barbier M; Campbell JD; Bevere JR; Damron FH
    Vaccine; 2022 Aug; 40(35):5229-5240. PubMed ID: 35927132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    Peterson JT; Zareba AM; Fitz-Patrick D; Essink BJ; Scott DA; Swanson KA; Chelani D; Radley D; Cooper D; Jansen KU; Dormitzer PR; Gruber WC; Gurtman A
    J Infect Dis; 2022 Jun; 225(12):2077-2086. PubMed ID: 34637519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
    Halperin SA; Smith B; Russell M; Scheifele D; Mills E; Hasselback P; Pim C; Meekison W; Parker R; Lavigne P; Barreto L
    Pediatr Infect Dis J; 2000 Apr; 19(4):276-83. PubMed ID: 10783014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.